Abu Dhabi – Mubasher: Gulf Pharmaceutical Industries (Julphar) has reached an exclusive license and production agreement with Quantum Genomics, a France-based biopharmaceutical company, to market and produce firibastat.
Through its manufacturing facilities in Ras Al Khaimah, Julphar will be Quantum's exclusive production partner and will receive exclusive rights to market firibastat in the Middle East, all African countries, the Commonwealth of Independent States, and Turkey, according to a press release on Monday.
This launch will meet the medical needs of up to 25% of all hypertension patients who are difficult to be treated with available therapy alternatives.
Julphar’s CEO, Essam Mohammed, said: "The new landmark agreement brings together a stronger focus on innovative ways to address critical diseases in the MENA region through manufacturing high-quality medications locally."
Meanwhile, the CEO of Quantum Genomics, Jean-Philippe Milon, commented: "Julphar is also amongst the region’s largest producers and is the ideal partner to support firibastat’s future production needs. We’re already exploring how Julphar could meet some of those requirements for the United States and Europe."